Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,002 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 035 Hot Springs, Arkansas, United States
  • Local Institution - 641 Cerritos, California, United States
  • Local Institution - 681 Fountain Valley, California, United States
  • Local Institution - 047 Los Angeles, California, United States
View all 259 locations
View Trial Details
Active, Not Recruiting

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

NCT05393804

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Local Institution - 0046 Mobile, Alabama, United States
  • Local Institution - 0005 Cerritos, California, United States
  • Local Institution - 0190 Irvine, California, United States
  • Local Institution - 0187 Los Angeles, California, United States
View all 207 locations
View Trial Details
Active, Not Recruiting

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06223516

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Arizona /ID# 260799 Phoenix, Arizona, United States
  • Mayo Clinic Hospital Jacksonville /ID# 262808 Jacksonville, Florida, United States
  • Sylvester Comprehensive Cancer Center /ID# 260798 Miami, Florida, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 261050 Ann Arbor, Michigan, United States
View all 15 locations
View Trial Details
Active, Not Recruiting

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04756726

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +20 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • University of California-San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute (Sarah Cannon Research Institute) Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

NCT04268498

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Miami Miami, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details

Related conditions